PALISADE BIO, INC. PALI
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
3/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $0 | -$16.8M | — | — | $129.4M |
| 2024 | $0 | -$14.4M | — | -$12.2M | $7.5M |
| 2023 | $300,000 | -$12.3M | — | -$11.1M | $11.3M |
| 2022 | $0 | -$14.3M | — | -$13.4M | $12.5M |
| 2021 | — | -$26.6M | — | -$14.8M | $7.4M |
| 2020 | $13,520 | -$10.3M | — | -$4.8M | -$16.6M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Baltera Robert Jr. | director | 2026-06-10 | Grant | 336,904 | — |
| Wei Binxian | director | 2026-06-10 | Grant | 592,300 | — |
| Wei Binxian | director | 2026-06-10 | Option exercise | 20,200 | — |
| Williams Donald Allen | director | 2026-06-10 | Grant | 1,498,900 | — |
| Williams Donald Allen | director | 2026-06-10 | Option exercise | 60,666 | — |
| Chuang Emil | director | 2026-06-10 | Grant | 592,300 | — |
| Chuang Emil | director | 2026-06-10 | Option exercise | 20,200 | — |
| Zwick Jordan Michael | director | 2026-06-10 | Grant | 336,904 | — |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Source: SEC EDGAR filings · CIK 0001357459 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.